AnaptysBio Inc (ANAB)vsRegeneron Pharmaceuticals Inc (REGN)
ANAB
AnaptysBio Inc
$50.50
+1.75%
HEALTHCARE · Cap: $1.39B
REGN
Regeneron Pharmaceuticals Inc
$813.27
-0.35%
HEALTHCARE · Cap: $81.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 14543% more annual revenue ($15.53B vs $106.09M). ANAB leads profitability with a 247.0% profit margin vs 27.9%. REGN earns a higher WallStSmart Score of 66/100 (B-).
ANAB
Hold46
out of 100
Grade: D+
REGN
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.6%
Fair Value
$160.49
Current Price
$50.50
$109.99 discount
Margin of Safety
+42.1%
Fair Value
$1389.86
Current Price
$813.27
$576.59 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 247 of every $100 in revenue as profit
Strong operational efficiency at 53.4%
Revenue surging 23.5% year-over-year
Strong operational efficiency at 33.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 140.3x book value
ROE of -210.1% — below average capital efficiency
Weak financial health signals
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : ANAB
The strongest argument for ANAB centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 247.0% and operating margin at 53.4%. Revenue growth of 23.5% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 27.9% and operating margin at 33.1%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : ANAB
The primary concerns for ANAB are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 25.47 is elevated, increasing financial risk.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
ANAB carries more volatility with a beta of 0.45 — expect wider price swings.
ANAB is growing revenue faster at 23.5% — sustainability is the question.
REGN generates stronger free cash flow (334M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (66/100 vs 46/100), backed by strong 27.9% margins and 16.7% revenue growth. ANAB offers better value entry with a 65.6% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AnaptysBio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?